The complaints allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 ...
SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ: DXCM) ...
What Is The Lawsuit About? The lawsuit has been filed on behalf of investors who purchased securities during the period of July 26, 2024 through September 17, 2025, inclusive (“the Class Period”). The ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback